Traditional syn-bio companies are dead – too hard to make the product and making them profitable is impossible
Jo Zayner, 23, (Jo Zayner, Dr. Jo Zayner is a visionary biochemist and genetic designer. For over 15 years, they have pioneered work in the field of bioengineering, publishing a number of scientific papers on the topic. Jo received their PhD in Biophysics from the University of Chicago, winning several awards for their work on engineering proteins. They then spearheaded work on developing engineered microbes for Mars terraforming at NASA, eventually leaving to start The ODIN, a bioengineering company based in Austin, Texas that is working to make genetic engineering accessible to everyone. Zayner’s groundbreaking work in human genetic engineering and medicine has been the focus of many documentaries, including the Netflix documentary Unnatural Selection and the NYT documentary Gut Hack. They have been made fun of on Last Week Tonight with John Oliver and written about in media all over the world including The New York Times, The New Yorker, El País, Le Monde, Time, Scientific American and NPR, among others., Phd, 1-2-2023, The death of SynthBio companies and my other predictions for Biotech in 2023, https://amateurgods.substack.com/p/the-death-of-synthbio-companies-and, 6-30-2023) SCade
The death of the synthetic biology company and the rise of consumer biotech. I’ma be honest, I’ve been pushing on the consumer biotech thing before everyone else thought it was cool. Growth for a company in the consumer space can take advantage of modern marketing techniques and the network effects and virality on social media. At The ODIN we have always sold our genetic engineering kits directly to consumers. Until around 2018ish the only really consumer biotech companies were fake meat companies like Memphis Meats aka Upside Foods. Even then, they aren’t real consumer companies because none of them have actually ever brought a biotech product to the consumer market. However, in the past few years we have seen a pivot of many traditional “Synthetic Biology” companies to making consumer products. Amyris, Bolt Threads, Geltor and others have pivoted to the cosmetics and beauty market. We are starting to see the failure of the platform/foundry style synthetic biology business model because creating synthetic biology products period, much less ones that can generate revenue, is a toughy even for the big names likes Gingko Bioworks and Amyris. I imagine that's why Amyris shifted and is set to bring in over $150 million in 2022 from consumer products alone and have been growing around 100% year over year. Look for consumer biotech companies to get even hotter.